We are live on ! Find out more
DNA icon

Ginkgo Bioworks

7.46 USD
-0.74
9.02%
At close Updated Nov 20, 4:00 PM EST
Pre-market
After hours
7.55
+0.09
1.21%
1 day
-9.02%
5 days
-19.78%
1 month
-24.34%
3 months
7.18%
6 months
-3.37%
Year to date
-14.25%
1 year
-4.6%
5 years
-98.62%
10 years
-98.47%
 

About: Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

Employees: 485

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 10.5%
Neutral 68.4%
Negative 21.1%
Neutral
The Motley Fool
3 days ago
Is Anthropic's IPO a Good Reason to Buy Ginkgo Bioworks Right Now?
Anthropic will soon go public. It's already investing in research automation for bioscience, including in robotics.
Is Anthropic's IPO a Good Reason to Buy Ginkgo Bioworks Right Now?
Neutral
The Motley Fool
14 days ago
Ginkgo Bioworks: 3 Key Takeaways for Long-Term Investors
Novo Nordisk selected Ginkgo to build an autonomous research laboratory. Ginkgo ended the third quarter with $285 million in cash.
Ginkgo Bioworks: 3 Key Takeaways for Long-Term Investors
Neutral
MarketBeat
15 days ago
Ginkgo Bioworks Q3 Earnings Call Highlights
Ginkgo Bioworks NYSE: DNA reported lower third-quarter revenue but narrowed its loss as restructuring-related expense cuts took hold, while executives highlighted new customers for its autonomous laboratory systems and cloud-based lab services.
Ginkgo Bioworks Q3 Earnings Call Highlights
Neutral
Seeking Alpha
16 days ago
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2026 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2026 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2026 Earnings Call Transcript
Neutral
Business Wire
16 days ago
Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo
BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”) today announced its results for the third quarter of 2026 that ended September 30, 2026. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information, will be available at investors.ginkgobioworks.com. Third Quarter 2026 Financial Results Third quarter 2026 Revenue of $28 million compared to $29 million in the comparable prior year perio.
Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo
Negative
Zacks Investment Research
23 days ago
Ginkgo Bioworks Holdings, Inc. (DNA) Suffers a Larger Drop Than the General Market: Key Insights
Ginkgo Bioworks Holdings, Inc. (DNA) closed at $12.74 in the latest trading session, marking a -4.35% move from the prior day.
Ginkgo Bioworks Holdings, Inc. (DNA) Suffers a Larger Drop Than the General Market: Key Insights
Negative
Zacks Investment Research
1 month ago
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know
Ginkgo Bioworks Holdings, Inc. (DNA) reached $9.86 at the closing of the latest trading day, reflecting a -2.09% change compared to its last close.
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know
Negative
Zacks Investment Research
1 month ago
Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Market
In the most recent trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $11.53, indicating a -1.96% shift from the previous trading day.
Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Market
Neutral
Benzinga
1 month ago
What's Going on With Ginkgo Bioworks Stock on Friday?
Ginkgo Bioworks Inc. (NYSE:DNA) is strengthening national biotechnology infrastructure by granting remote laboratory access through the National Science Foundation's X-Labs program and integrating high-speed cellular imaging tools into its Boston facility.
What's Going on With Ginkgo Bioworks Stock on Friday?
Neutral
Business Wire
1 month ago
Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science Program
BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks (NYSE: DNA) today announced that it will provide in-kind access to its autonomous laboratory in Boston to support the National Science Foundation's X-Labs program. Ginkgo's support was announced today by Michael Kratsios, Director of the White House Office of Science and Technology Policy (OSTP), at the Science: A New Golden Age Summit in Washington, D.C. NSF X-Labs is a $1.5 billion, decade-long initiative to fund independent teams of researchers, engin.
Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science Program
Price charts implemented using Lightweight Charts™